Pharmafocus
Pharmaceutical Industry news, analysis and insights
The latest European Pharmaceutical industry news
Following the increase in respiratory infections, the continuing cost of living crisis and the Russia-Ukraine conflict, Europe is planning countermeasures for further antibiotic shortages
AstraZeneca has announced plans to open a new facility in Ireland, previously planned for northwest England
Genoscience Pharma has received FDA ODD for its hepatocellular carcinoma drug
Regeneron Pharmaceuticals and Sanofi have announced that the European Commission (EC) has expanded the marketing authorisation for Dupixent® (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
ServBlock, an Irish start-up, and Irish Manufacturing Research (IMR), have been given EU funding to build a data exchange system for outsourced pharmaceutical manufacturing.
Recently, AstraZeneca announced two drug approvals in the European Union (EU), the first being Imfinzi’s approval for the treatment of biliary tract cancer, and the latter being Lynparza for prostate cancer.
Polish clinical stage biotechnology company Molecure has announced its third quarter results for the period ending 30 September 2022. Its press release also mentions its plans for its R&D day in December, and its strategies and preparations for various phase 1 and 2 clinical trials.
Karyopharm Therapeutics and the Menarini Group’s Nexpovio (selinexor) has been granted orphan medicinal product designation by the European Commission (EC). The drug is intended to treat myelofibrosis (MF), a rare kind of bone marrow cancer.
AstraZeneca has announced that three of its drugs have been recommended for EU approval. The three drugs are: Imfinzi, Enhertu and Lynparza, all of which can be used to treat different cancers.
A team of scientists at the Technical University of Denmark have genetically engineered yeast to recreate vinblastine, an anti-cancer drug which was in short supply between 2019-2021. It is hoped this breakthrough will pave the way to creating more synthetic anti-cancer drugs.
The Swiss pharma group has agreed to buy Seattle-based biotech Good Therapeutics and its preclinical-stage PD-1 regulated IL-2 receptor agonist programme for $250 million upfront, with undisclosed milestone payments on offer tied to development, regulatory, and commercial objectives.
A team of scientists from the University of Copenhagen, Denmark have designed a sticky tape skin test which could help predict if young babies are likely to develop bad eczema, according to BBC News.